Sep. 12, 2019
Senate approves bill that would ban “pay-to-delay” schemes blamed for keeping generic drugs off the market
The bill invokes the Cartwright Act, a state antitrust law, and applies it to drug makers. But the situation AB 824 addresses was created in part by the Hatch-Waxman Act, a 1984 federal law intended to lower drug prices and speed generics to market.
The Senate approved a bill Wednesday that would ban "pay-to-delay" schemes blamed for keeping generic drugs off the market.
"Prescription drug prices are too damn high," said Sen. Robert Hertzberg, D-Van Nuys, while presenting AB 824. He said 17% of the cost of "overall health care services in the United States are prescription drugs."
The bill states that patent infringement claim settlement i...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In